Bicara Therapeutics Strengthens Board with Appointments of Jeremy Bender and Christy Oliger as Company Advances Ficerafusp Alfa Toward Commercialization
核心洞察
Bicara Therapeutics (搜索) appointed Jeremy Bender, Ph.D., and Christy Oliger to its Board of Directors, bringing extensive commercial and strategic expertise as the company transitions toward delivering ficerafusp alfa to patients.
Dr. Bender previously led Day One Biopharmaceuticals through its evolution into a commercial-stage oncology company, including the approval and launch of OJEMDA and a $2.5 billion acquisition by Servier in 2026.
Ms. Oliger, former SVP of the Oncology Business Unit at Genentech, managed a portfolio of 15 oncology products contributing over $13 billion in U.S. revenue and led launches across multiple cancer indications.
Bicara Therapeutics (搜索) Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company focused on developing transformative bifunctional therapies for solid tumors, announced on July 28, 2026, the appointments of Jeremy Bender, Ph.D., MBA, and Christy Oliger to its Board of Directors. The appointments come at what CEO Claire Mazumdar, Ph.D., MBA, described as a "pivotal time" for the company as it advances its lead program, ficerafusp alfa, through a registration-enabling clinical study and prepares for potential commercialization.
"We are delighted to welcome Jeremy and Christy to our Board of Directors at this pivotal time for Bicara. Together, they bring deep commercial, strategic, and operational expertise that will be invaluable as we continue our evolution from a clinical-stage organization to one focused on successfully delivering ficerafusp alfa to patients," said Mazumdar.
The company also announced the retirement of founding board member Kiran Mazumdar-Shaw. Mike Powell, Ph.D., Chairman of the Board, acknowledged her foundational role: "As one of our founding Board members, Kiran has been instrumental in shaping Bicara from its earliest days. Her impact extends beyond the initial seed capital that helped launch the company, but also the strategic guidance and steadfast support that has enabled Bicara to advance ficerafusp alfa into the clinic and reach the important milestone of a registration-enabling clinical study."
Deep Commercial and Strategic Expertise
Dr. Bender brings more than 20 years of corporate strategy and operating experience in biotechnology. He most recently served as Chief Executive Officer, President, and board member of Day One Biopharmaceuticals from September 2020 to April 2026, where he led the company's transition into a commercial-stage oncology organization. Under his leadership, Day One secured the approval and launch of OJEMDA for pediatric low-grade glioma (搜索) and completed its approximately $2.5 billion acquisition by Servier in 2026.
Prior to Day One, Dr. Bender held senior roles at Gilead Sciences as Vice President of Corporate Development, served as Chief Operating Officer at Tizona Therapeutics, and was Chief Business Officer at Sutro Biopharma. He currently serves on the boards of Mereo BioPharma Group plc and Aura Biosciences. Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an MBA from the MIT Sloan School of Management.
Ms. Oliger brings more than 30 years of commercial and operating experience in global biopharmaceutical organizations. As Senior Vice President and Business Unit Head for Oncology at Genentech from 2017 to 2020, she managed a portfolio of 15 products contributing U.S. revenue exceeding $13 billion and led launches in lung cancer, breast cancer, chronic lymphocytic leukemia, non-Hodgkin lymphoma, and melanoma, overseeing an organization of more than 800 people.
Prior to her oncology role, Ms. Oliger served as Senior Vice President and Business Unit Head for Neurology, Rare Disease, and Infectious Disease at Genentech, where she drove successful launches of Ocrevus for multiple sclerosis, Hemlibra for hemophilia, and Evrysdi for spinal muscular atrophy. She also spent three years as Global Head of Portfolio and Project Management, overseeing a late-stage development portfolio of more than 300 projects. Ms. Oliger currently serves on the boards of Vera Therapeutics, Karyopharm Therapeutics, and Replimune Inc., and holds a B.A. in Economics from the University of California, Santa Barbara.
Ficerafusp Alfa: A Bifunctional Approach to Solid Tumors
Bicara's lead program, ficerafusp alfa (formerly BCA101), is a bifunctional therapy combining an epidermal growth factor receptor (EGFR (搜索))-directed monoclonal antibody with a human transforming growth factor beta (TGF-β (搜索)) ligand trap. The dual-targeting approach is designed to simultaneously block cancer cell-intrinsic EGFR survival and proliferation signaling while inhibiting immunosuppressive TGF-β signaling within the tumor microenvironment.
By directing the TGF-β (搜索) inhibitor into the immediate tumor microenvironment through EGFR (搜索) binding on tumor cells, Bicara aims to achieve deep and durable responses with improved overall survival while reducing the adverse effects historically associated with systemic TGF-β inhibition. Ficerafusp alfa is currently being developed for head and neck squamous cell carcinoma (搜索), an indication with significant unmet need, as well as other solid tumor types.
"Each of these distinguished professionals has an established track record of guiding innovative biopharmaceutical companies through critical stages of growth, including pipeline development, corporate strategy, and commercialization," Mazumdar added. "Their perspectives will strengthen our Board as we advance our portfolio, execute on our long-term vision, and continue building Bicara into a mature biopharmaceutical organization."